[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaginal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaginal-cancer":51},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,66,136,162,225,261,294,320,345,370,392,422,443,492,524,550,573,608,632,652],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100602476","destiny-pantumour04-100602476",false,"NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","ALL","18 Years","130 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Sarcoma","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","RECRUITING","2026-06-26",{"date":56,"type":57},"2026-06-29","ACTUAL",{"date":59,"type":57},"2025-09-18",{"date":61,"type":22},"2028-03-30",{"name":63,"class":64},"AstraZeneca","INDUSTRY",17,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":78,"studyType":23,"phases":4,"briefSummary":79,"conditions":80,"keywords":116,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":135},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"19 Years","110 Years",{"count":77,"type":22},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[41,49,81,31,82,83,84,85,27,86,87,88,89,35,90,91,92,93,28,94,95,42,47,96,50,97,98,99,100,101,102,103,104,44,105,106,107,108,109,110,36,45,111,112,40,30,51,113,114,115],"Lung Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Kidney Cancer","Penile Cancer","Ureter Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Unknown Primary Tumor","Multiple Myeloma","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[41,49,117,118,119,120,121,122,123,124,109,125,114,115],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":56,"type":57},{"date":129,"type":57},"2013-11-01",{"date":131,"type":22},"2099-12",{"name":133,"class":134},"University of Nebraska","OTHER",42,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":147,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100542204","ask-questions-in-gynecologic-oncology-asq-gyo-100542204","NCT06339827","ASk Questions in GYnecologic Oncology (ASQ-GYO)","ASk Questions in GYnecologic Oncology (ASQ-GYO): A Randomized Controlled Trial of a Question Prompt List Communication Intervention in Outpatient Gynecologic Oncology Clinics","ASQ-GYO","Inclusion Criteria:\n\n* 18 years of age\n* Understands spoken and written English\n* Able to consent to study participation\n* Biopsy confirmed gynecologic cancer diagnosis (ovarian, endometrial, cervical, vulvar, or vaginal cancer or Gestational Trophoblastic Disease) OR have imaging and\u002For laboratory findings highly concerning for a cancer diagnosis and have not seen a Gynecologic Oncologist\n\nExclusion Criteria:\n\n* pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)\n* History and\u002For imaging\u002Flaboratory findings more indicative of a non-cancer diagnosis\n* Previous treatment discussion with a Gynecologic Oncologist",{"count":145,"type":22},70,"INTERVENTIONAL",[148],"NA","The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge compared to usual care during new patient gynecologic oncology visits. Also to determine the acceptability of the ASQ-GYO QPL with new gynecologic oncology patients.",[40,30,29,52,51,151],"Gestational Trophoblastic Disease","2026-06-15",{"date":154,"type":57},"2026-06-17",{"date":156,"type":57},"2024-04-04",{"date":158,"type":22},"2028-05",{"name":160,"class":134},"Ira Winer",1,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":146,"phases":170,"briefSummary":172,"conditions":173,"keywords":190,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100491983","phase-2-e7-tcr-t-cell-immunotherapy-for-human-papillomavirus-hpv-associated-cancers-100491983","NCT05686226","E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers","A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated Cancers","Inclusion Criteria: Subjects must meet all the following criteria to participate in this study.\n\n1. Histologically or cytologically confirmed metastatic or refractory\u002Frecurrent HPV-16+ cancer.\n2. Tumor and\u002For blood with HPV16 genotype as determined by testing performed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.\n3. HLA-A\\*02:01 allele as determined by testing performed in a CLIA certified laboratory. Participants may be enrolled based on low resolution typing (i.e., HLA-A\\*02) but the HLA-A\\*02:01 allele type must be confirmed prior to apheresis.\n4. Measurable disease as assessed by RECIST Criteria Version 1.1.\n5. Age ≥ 18 years.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at screening.\n7. Must have received prior first line standard therapy or have declined standard therapy.\n8. Standard treatment options for first and second-line therapy must be presented and formally declined (Appendix VII).\n9. Patients with three or fewer brain metastases that have been treated with surgery or stereotactic radiosurgery are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month before protocol treatment. Patients must be fully recovered from surgery.\n10. Negative pregnancy test for women under 55 and all women who have had a menstrual period in the last 12 months. A pregnancy test is not required for women who have had a bilateral oophorectomy or hysterectomy.\n11. Men and women of child-bearing potential must agree to use adequate contraception (i.e., intrauterine device, hormonal barrier method of birth control, abstinence, tubal ligation, or vasectomy) prior to study entry and for four months after treatment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n12. Seronegative for HIV antibody, hepatitis B antigen (HBsAg), and hepatitis C antibody. If a hepatitis C antibody test is positive, then testing for antigen by RT-PCR for hepatitis C (HCV) RNA must be negative.\n13. Participants must have organ and marrow function as defined below:\n\n    1. Leukocytes \\> 3,000\u002FmcL\n    2. Absolute neutrophil count \\> 1,500\u002FmcL\n    3. Platelets \\> 100,000\u002FmcL\n    4. Hemoglobin \\> 9.0 g\u002FdL\n    5. Total bilirubin within normal institutional limits except in participants with Gilbert's Syndrome who must have a total bilirubin \\\u003C 3.0 mg\u002FdL.\n    6. Serum aspartate transferase (AST) (SGOT)\u002Falanine transaminase (ALT) (SGPT) \\\u003C 2.5 x upper limit of normal (ULN)\n    7. Calculated creatinine clearance (CrCl) \\>50 mL\u002Fmin\u002F1.73 m2 for participants with creatinine levels above institutional normal (by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation).\n    8. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤1.5 X ULN unless the subject is receiving anticoagulant therapy. Subjects on anticoagulant therapy must have a PT or aPTT within therapeutic range and no history of severe hemorrhage.\n14. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the E7 TCR cells. Adverse events from prior therapy must have resolved to ≤ grade 1 according to CTCAE Version 5.0 or have demonstrated clinical stability for the protocol.\n15. Participants must be able to understand and be willing to sign the written informed consent document.\n16. Participants must agree to participate in Rutgers protocol 192103 (Pro2021002307) for gene therapy long term follow up and in Rutgers protocol 192002 (Pro2021000281) or NIH protocol 16C0061 (Rutgers 192202) for biospecimen collection study.\n\nNote: Participants may have undergone minor surgical procedures with the past three weeks, as long as all toxicities have recovered to Grade 1 or less.\n\nExclusion Criteria: Subjects who meet any of the following criteria will be excluded from participation in this study:\n\n1. Uncontrolled intercurrent illness such as active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations at the time of treatment that would limit compliance with study requirements.\n2. History of severe allergic reactions to compounds of similar chemical or biological composition to agents used in this study.\n3. History of coronary revascularization or ischemic symptoms unless patient has a normal cardiac stress test.\n4. Documented LVEF of less than or equal to 45% tested. The following participants will undergo cardiac evaluations:\n\n   1. Clinically significant atrial and\u002For ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or\n   2. Age ≥ 50 years old\n5. Participants with baseline screening pulse oxygen level of ≤ 92% on room air will not be eligible. If the underlying cause of hypoxia improves, then they may be reevaluated.\n6. Subjects with HLA-A\\*02:01 damaging mutation or allele loss detected by clinical or research genomic profiling will not be eligible.\n7. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with E7 TCR T cells, breastfeeding should be discontinued if the mother is treated with E7 TCR T cells. These potential risks may also apply to other agents used in this study.\n8. Participants with a systemic immunodeficiency including acquired deficiency such as HIV or primary immunodeficiency such as Severe Combined Immunodeficiency Disease are ineligible. The experimental treatment being evaluated in this protocol depends on an intact immune system. Participants who have decreased immune competence may be less responsive to the treatment.\n9. Participants on immunosuppressive drugs including corticosteroids unless meeting criteria outlined in Section 6.1 (Prohibited Medications).\n10. Participants with potentially severe autoimmune diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, autoimmune hepatitis, autoimmune pancreatitis, or systemic lupus erythematosus are not eligible. Patients with less severe autoimmune diseases such as hypothyroidism, vitiligo, and other minor autoimmune disorders are eligible.\n11. Participants with prior or concurrent malignancy whose natural history or treatment is unlikely to interfere with the safety or efficacy assessments of the investigational regimen are eligible for this trial. Examples include, but are not limited to:\n\n    1. Carcinoma in situ\n    2. Cutaneous skin cancers requiring only local excision\n    3. Low grade non-muscle invasive bladder cancer\n    4. Low grade prostate cancer\n\n    Participants with prior or concurrent malignancy that do not meet the above criteria are excluded.\n12. Subjects who received a live vaccine within 30 days prior to enrollment are not eligible.\n13. Determination by the Principal Investigator that participation is not in the best interest of the research subject or may jeopardize the safety of the subject or integrity of the clinical trial data.\n14. Current treatment with another investigational agent.",{"count":5,"type":22},[171],"PHASE2","This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.",[29,48,174,27,175,51,95,176,177,178,179,180,181,182,183,184,185,186,187,188,189],"Oropharynx Cancer","Vulva Cancer","Metastatic Cancer","HPV-Related Malignancy","HPV-Related Carcinoma","HPV-Related Cervical Carcinoma","HPV-Related Squamous Cell Carcinoma","HPV-Related Adenocarcinoma","HPV Positive Oropharyngeal Squamous Cell Carcinoma","HPV-Associated Vaginal Adenocarcinoma","HPV-Related Adenosquamous Carcinoma","HPV-Related Endocervical Adenocarcinoma","HPV-Related Anal Squamous Cell Carcinoma","HPV-Related Penile Squamous Cell Carcinoma","HPV-Related Vulvar Squamous Cell Carcinoma","HPV Positive Rectal Squamous Cell Carcinoma",[191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214],"Chimeric antigen receptors (CAR-T)","Tumor infiltrating lymphocyte","TCR-T","immunotherapy","T cell","adoptive cell therapy","cellular therapy","gene therapy","human papillomavirus","HPV","E7","T cell receptor","TCR","E7 TCR","lymphocyte","cell therapy","cervical cancer","oropharyngeal cancer","anal cancer","vulvar cancer","vaginal cancer","penile cancer","tumor infiltrating lymphocytes (TIL)","TIL therapy","2026-06-10",{"date":217,"type":57},"2026-06-12",{"date":219,"type":57},"2023-03-07",{"date":221,"type":22},"2027-01-01",{"name":223,"class":134},"Christian Hinrichs",3,{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":146,"phases":234,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":260},"100488427","phase-1-e7-t-cell-receptor-tcr--t-cell-induction-therapy-for-locoregionally-advanced-hpv-associated-cancers-100488427","NCT05639972","E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers","A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers","Inclusion Criteria: Subjects must meet all the following criteria to participate in this study.\n\n1. Histologically confirmed carcinoma of a primary tumor site and stage indicated in Table 3 of the protocol.\n2. Tumor with HPV16 genotype as determined by testing performed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.\n3. HLA-A\\*02:01 allele determined by testing performed in a CLIA certified laboratory. Participants may be enrolled based on low resolution typing (i.e., HLA-A\\*02) but the HLA-A\\*02:01 allele type must be confirmed prior to apheresis.\n4. Measurable disease per RECIST Criteria Version 1.1 or PERCIST.\n5. Age ≥ 18 years.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.\n7. Negative pregnancy test for women under 55 and all women who have had a menstrual period in the last 12 months. A pregnancy test is not required for women who have had a bilateral oophorectomy or hysterectomy.\n8. Men and women of child-bearing potential must agree to use adequate contraception (i.e., intrauterine device, hormonal barrier method of birth control, abstinence, tubal ligation, or vasectomy) prior to study entry and for four months after treatment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n9. Seronegative for HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C antibody. If a hepatitis C antibody test is positive, then testing for antigen by reverse transcription polymerase chain reaction (RT-PCR) must be negative.\n10. Participants must have organ and marrow function as defined below:\n\n    1. Leukocytes \\> 3,000\u002FmcL\n    2. Absolute neutrophil count \\> 1,500\u002FmcL\n    3. Platelets \\> 100,000\u002FmcL\n    4. Hemoglobin \\> 9.0 g\u002FdL\n    5. Total bilirubin within normal institutional limits except in participants with Gilbert's Syndrome who must have a total bilirubin \\\u003C 3.0 mg\u002FdL.\n    6. Serum aspartate aminotransferase (AST) (SGOT)\u002F alanine transaminase (ALT) (SGPT) \\\u003C 2.5 x upper limit of normal (ULN)\n    7. Calculated creatinine clearance (CrCl) \\>50 mL\u002Fmin\u002F1.73 m2 for participants with creatinine levels above institutional normal (by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation).\n    8. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤1.5 X ULN unless the subject is receiving anticoagulant therapy. Subjects on anticoagulant therapy must have a PT or aPTT within therapeutic range and no history of severe hemorrhage.\n11. Participants must be able to understand and be willing to sign the written informed consent document.\n12. Participants must agree to participate in Rutgers protocol 192103 (Pro2021002307) for gene therapy long term follow up and in Rutgers protocol 192002 (Pro2021000281) for biospecimen studies.\n\nNote: Patients may have undergone minor surgical procedures with the past three weeks, as long as all toxicities have recovered to Grade 1 or less.\n\nExclusion Criteria: Subjects who meet any of the following criteria will be excluded from participation in this study:\n\n1. Have received prior systemic therapy or definitive chemoradiation for the cancer that is being treated on this protocol. Palliative radiation therapy for symptom management, such as to control tumor-induced bleeding, is permitted.\n2. Current treatment with another investigational agent.\n3. History of severe allergic reactions to compounds of similar chemical or biological composition to agents used in this study.\n4. Uncontrolled intercurrent illness such as active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations at the time of treatment that would limit compliance with study requirements.\n5. Subjects with HLA-A\\*02:01 damaging mutation or allele loss detected by research or clinical sequencing will not be eligible.\n6. Documented LVEF of less than or equal to 45% tested. The following participants will undergo cardiac evaluations:\n\n   1. Clinically significant atrial and\u002For ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or\n   2. Age ≥ 50 years old\n7. Participants with baseline screening pulse oxygen level of ≤ 92% on room air will not be eligible. If the underlying cause of hypoxia improves, they may be reevaluated.\n8. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with E7 TCR T cells, breastfeeding should be discontinued if the mother is treated with E7 TCR T cells. These potential risks may also apply to other agents used in this study.\n9. Participants with a systemic immunodeficiency including acquired deficiency such as HIV or primary immunodeficiency such as Severe Combined Immunodeficiency Disease are ineligible. The experimental treatment being evaluated in this protocol depends on an intact immune system. Participants who have decreased immune competence may be less responsive to the treatment.\n10. Participants on immunosuppressive drugs including corticosteroids unless meeting criteria outlined in Section 6.1 (Prohibited Medications).\n11. Participants with potentially severe autoimmune diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, autoimmune hepatitis, autoimmune pancreatitis, or systemic lupus erythematosus are not eligible. Patients with less severe autoimmune diseases such as hypothyroidism, vitiligo, and other minor autoimmune disorders are eligible.\n12. Participants with prior or concurrent malignancy whose natural history or treatment is unlikely to interfere with the safety or efficacy assessments of the investigational regimen are eligible for this trial. Examples include, but are not limited to:\n\n    1. Carcinoma in situ\n    2. Cutaneous skin cancers requiring only local excision\n    3. Low grade non-muscle invasive bladder cancer\n    4. Low grade prostate cancer\n13. Subjects who received a live vaccine within 30 days prior to enrollment are not eligible.\n14. Determination by the Principal Investigator that participation is not in the best interest of the research subject or may jeopardize the safety of the subject or integrity of the clinical trial data.",{"count":233,"type":22},15,[235,171],"PHASE1","The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. The intent of E7 TCR-T cell treatment is to shrink or eliminate tumors and thereby facilitate definitive therapy and increase overall survival.\n\nThis study seeks to determine 1) if E7 TCR-T cells can be administered without undue delay in definitive treatment, 2) the tumor response rate to E7 TCR-T cell treatment, and 3) the disease-free survival rate at 2 and 5 years.\n\nParticipants will undergo an apheresis procedure to obtain T cells that will be genetically engineered to generate E7 TCR-T cells. They will receive a conditioning regimen, a single infusion of their own E7 TCR-T cells, and adjuvant aldesleukin. Participants will follow up to assess safety and determine tumor response and will return to their primary oncology team for definitive therapy.",[238,178,177,182,181,184,180,186,187,188,185,29,174,27,52,95,51],"HPV-Associated Cervical Carcinoma",[200,240,241,242,243,244,245,192,203,195,246,247,248,249,250,251,252,253],"Cell therapy","Adoptive cell therapy","Immunotherapy","Radiation","Chemoradiation","CAR-T, cell therapy","Gene therapy","Cervical cancer","Oropharyngeal cancer","Anal cancer","Vulvar cancer","Vaginal cancer","Penile cancer","Induction therapy",{"date":217,"type":57},{"date":256,"type":57},"2025-08-11",{"date":258,"type":22},"2026-10-01",{"name":223,"class":134},2,{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":268,"minAge":269,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":146,"phases":272,"briefSummary":273,"conditions":274,"keywords":278,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":161},"100496383","physical-activity-intervention-among-older-women-with-gynecologic-cancers-fit4treatment-100496383","NCT05743517","Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)","Patient-Tailored Physical Activity Intervention Among Older Women With Gynecologic Cancers Undergoing Chemotherapy (Fit4Treatment)","Inclusion Criteria:\n\n* Female; \\> 60 years of age\n* Diagnosis of endometrial\u002Futerine, ovarian, cervical or vulvar\u002Fvaginal cancer\n* Undergoing or planning to undergo any systemic treatment for a gynecologic malignancy (e.g., chemotherapy, immunotherapy, anti-angiogenic therapies, targeted therapies, etc.)\n* Willing to try to identify an exercise partner to participate with them, if needed\n* Fluent in English\n\nExclusion Criteria:\n\n* Uncontrolled cardiovascular disease or other major contraindications to physical activity\n* Active brain metastases\n* Cognitive or functional limitations that preclude a patient's ability to participate in the physical activity intervention\n* Pregnant women or prisoners","FEMALE","60 Years",{"count":271,"type":22},192,[148],"The primary purpose of the study is to determine which of four components (symptom-burden tailored app, exercise partner, oncology provider engagement, coaching) added to a core intervention of a wearable activity tracker and commercially available app, will improve physical activity. The findings will generate meaningful knowledge about how to best increase physical activity in older gynecologic cancer patients receiving systemic cancer therapies to improve quality of life and cancer-specific survival.",[275,30,276,29,277,52,51],"Ovary Cancer","Uterine Cancer","Cervix Cancer",[279,280,281,282,283,284],"behavioral intervention","physical activity","cancer outcomes","chemotherapy","systemic therapy","quality of life","2026-05-27",{"date":287,"type":57},"2026-05-29",{"date":289,"type":57},"2023-09-15",{"date":291,"type":22},"2029-08-01",{"name":293,"class":134},"Northwestern University",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":268,"minAge":18,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":146,"phases":303,"briefSummary":304,"conditions":305,"keywords":309,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":161},"100514523","phase-2-using-reiki-therapy-to-improve-symptoms-associated-with-brachytherapy-in-patients-with-gynecological-malignancies-100514523","NCT05979610","Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies","Reiki-Brachy: An Interventional Treatment Trial Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies","Reiki-Brachy","Inclusion Criteria:\n\n* Subject aged ≥ 18 years.\n* Pathologically confirmed malignancy of the endometrium, cervix, vagina or vulva.\n* Eligible to undergo brachytherapy treatment as an outpatient procedure.\n* Able to read and understand English and\u002For Spanish.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Willing to participate in either the Reiki therapy or standard of care arm regardless of treatment assignment.\n\nExclusion Criteria:\n\n* Prior brachytherapy treatment for a gynecological malignancy.\n* Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.",{"count":145,"type":22},[171],"The goal of this open label, randomized, controlled clinical trial is to assess the benefits of providing Reiki therapy to subjects receiving their first brachytherapy treatment for gynecological malignancies.\n\nParticipants will either receive a session of Reiki therapy or usual care during the standard wait time between the placement of the brachytherapy device and brachytherapy treatment. Questionnaires will be administered at various time points on the day of the participant's first brachytherapy treatment as well as at the three month follow-up time point.\n\nResearchers will compare the intervention (Reiki therapy) and control (usual care) groups to assess the impact of the Reiki therapy on anxiety, pain, state anxiety, depression, and physiological measurements.",[306,307,308,30,29,51,52],"Gynecologic Neoplasm","Brachytherapy","Therapeutic Touch",[310],"Reiki","2026-05-06",{"date":313,"type":57},"2026-05-11",{"date":315,"type":57},"2023-11-14",{"date":317,"type":22},"2027-06",{"name":319,"class":134},"University of Utah",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":268,"minAge":18,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":146,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":335,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":4},"100633166","assessment-of-sexual-quality-of-life-following-local-treatment-radiotherapy-with-or-without-surgery-in-patients-with-hpv-positive-pelvic-cancer-a-descriptive-longitudinal-study-100633166","NCT07523152","Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal Study","SAPPHIRE","Inclusion Criteria:\n\n1. Women aged 18 or over.\n2. Sexually active patients, i.e. those who have been sexually active in the year prior to their cancer diagnosis.\n3. Patients being treated at the Montpellier Cancer Institute (ICM).\n4. Patient with pelvic squamous cell carcinoma (cervix, vagina, vulva or anus) and human papillomavirus (HPV+) infection\n5. Patient aware of her HPV status and how it is transmitted.\n6. Indicated for external radiotherapy\n7. Patient who has not received any oncological treatment prior to inclusion.\n8. Patient who has given verbal consent.\n\nExclusion Criteria:\n\n1. Patients receiving radiotherapy treatment outside the Montpellier Cancer Institute (ICM).\n2. Patients who are unwilling or unable to complete the study questionnaires.\n3. Patients under guardianship, curatorship or court protection,\n4. Patients for whom regular follow-up is impossible for psychological reasons,\n5. Patients who do not speak French.",{"count":135,"type":22},[148],"In patients with cancer associated with human papillomavirus (HPV), the physical effects of treatment, combined with the psychosexual impact linked to HPV status, can further impair the quality of sexual life.\n\nHowever, few studies have examined the specific effect of HPV status (or knowledge of status) on the recovery\u002Fquality of sexuality following radiotherapy.\n\nIt is against this backdrop that we propose a prospective longitudinal study specifically dedicated to investigating the sexual quality of life of women with HPV-positive pelvic cancer.\n\nThis type of study will enable better quantification and description of sexual dysfunction occurring after treatment, and assessment of the impact of HPV carriage, with the future aim of guiding new prevention and management strategies.",[331,27,51],"Pelvic Cancer",[211,333,334],"uterus cancer","anal canal cancer","NOT_YET_RECRUITING","2026-04-04",{"date":338,"type":57},"2026-04-13",{"date":340,"type":22},"2026-04-02",{"date":342,"type":22},"2027-10-31",{"name":344,"class":134},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":268,"minAge":18,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":146,"phases":354,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":161},"100549320","3d-printed-custom-applicators-for-hdr-bt-disco-100549320","NCT06432478","3D Printed Custom Applicators for HDR BT (DISCO)","Study of 3D-printed Custom Applicators for Intracavitary HDR Gynaecological Brachytherapy (DISCO)","Inclusion Criteria:\n\n* Able to give informed consent\n* Patients indicated for intracavitary brachytherapy\n* FIGO stage I-IVA\n* ECOG 0-2\n* Primary endometrial cancer, primary vaginal cancer, primary vulva cancer, recurrent gynaecological cancer\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients contraindicated for brachytherapy\n* Inflammatory bowel disease\u002Fhistory of adhesions\u002Fbowel obstruction\n* Renal transplant\u002Fhorseshoe kidney\n* Patients with significant LVSI or pelvic sidewall invasion\n* Patients requiring interstitial brachytherapy implants",{"count":353,"type":22},10,[148],"Intracavitary brachytherapy for gynaecological cancer currently use cylinder-type applicators or custom wax moulds to place a radioactive source in close proximity to the treatment area and provide highly conformal dose distributions. This study is a Phase IIa non-randomised interventional pilot trial that will investigate the feasibility of successfully treating patients with 3D-printed custom applicators.",[357,30,51,175],"Gynecologic Cancer",[359,360,307],"3D-printed applicator","Gynaecological Cancer","2026-02-04",{"date":363,"type":57},"2026-02-06",{"date":365,"type":57},"2023-11-24",{"date":367,"type":22},"2028-09",{"name":369,"class":134},"Royal North Shore Hospital",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":268,"minAge":18,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":146,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":161},"100285304","image-guided-gynecologic-brachytherapy-100285304","NCT02993900","Image-Guided Gynecologic Brachytherapy","A Clinical Trial To Evaluate Image-Guided Gynecologic Brachytherapy In The MR Simulator Suite","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed carcinoma. Central pathology review is not required; however, pathology will be reviewed at the SKCCC at Johns Hopkins.\n* Site\u002FStage\n* Any patient eligible for internal implantation without MR guidance will be considered eligible for this protocol. Standard criteria for internal implantation include:\n* Carcinoma of the cervix: Stage I-IVA or vaginal recurrence\n* Carcinoma of the uterus: Stage IIIB (vaginal involvement), inoperable, or vaginal recurrence\n* Carcinoma of the vagina: Stage I-IVA or vaginal recurrence\n* Carcinoma of the vulva: Stage I-IVA or recurrence\n* Carcinoma of the urethra based on treating physician's discretion\n* Patients who have received prior radiation or chemotherapy may be enrolled on this study.\n* Age \\> 18 years. Children do not develop these malignancies and therefore are not considered candidates for this trial.\n* Life expectancy of greater than 6 months.\n* ECOG performance status of \\\u003C2 or greater, based on treating physician's discretion\n* MRI of the pelvis or PET-CT within 4 months before registration\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Absolute neutrophil count \\\u003C 500 at the time of enrollment\n* A history of metal in the head or eyes","100 Years",{"count":379,"type":22},54,[148],"This research is being done to evaluate multimodality imaging, including magnetic resonance imaging-guided therapy (MRT), as a possible treatment for gynecologic cancers. The therapy takes place in the Department of Radiation Oncology at the Johns Hopkins SKCCC. The purpose of this study is to investigate the ability of MRI to successfully guide the placement of the brachytherapy applicator necessary to treat participants' gynecologic cancer. The Investigators want to see if the use of MRI will do a better job of assessing the tumor at the time of brachytherapy than the routinely used CT scan. The Investigators also want to determine if the use of MRI will enable doctors to reduce the radiation dose received by the body during the process of treating the tumor.",[29,276,51,52,28],"2025-12-16",{"date":385,"type":57},"2025-12-18",{"date":387,"type":57},"2016-12-15",{"date":389,"type":22},"2028-12",{"name":391,"class":134},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":268,"minAge":18,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":146,"phases":401,"briefSummary":402,"conditions":403,"keywords":405,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":260},"100568128","phase-2-belzutifan-in-recurrent-clear-cell-carcinoma-of-gynecologic-origin-100568128","NCT06677190","Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin","A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary or Clear Cell Carcinoma of Other Gynecologic Origin","Inclusion Criteria:\n\n* Participants must have histologically or cytologically confirmed recurrent or persistent clear cell carcinoma of the ovary (CCOC) or clear cell carcinoma of other gynecologic origin (e.g., endometrial, cervical, vaginal, vulvar, endometriosis-related). If mixed histology, then ≥50% clear cell component.\n* Participants must have measurable disease, defined as at least one lesion that can be accurately measured per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n* Participants must have received at least one prior platinum-based chemotherapeutic regimen for primary management of disease.\n* Prior bevacizumab is allowed.\n* Prior use of immunotherapy is allowed.\n* Unlimited prior lines for the treatment of recurrent or persistent disease are allowed.\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of Belzutifan in participants \\\u003C18 years of age, children are excluded from this study.\n* ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1 (Karnofsky performance scale ≥70%, see Appendix A).\n* Participants must meet the following organ and marrow function as defined below:\n\n  * Absolute neutrophil count ≥ 1,500\u002FmcL\n  * Hemoglobin ≥ 10.0 g\u002FdL (without use of erythropoietin; without packed red blood cell (RBC) transfusion within preceding 2 weeks)\n  * Platelets ≥ 100,000\u002FmcL\n  * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) OR direct bilirubin ≤ ULN for participants with total bilirubin levels \\> 1.5 ULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 2.5 × institutional upper limit of normal (ULN) (in the absence of liver metastases) or ≤ 5 x institutional ULN (in the presence of liver metastases)\n  * Creatinine ≤ 1.5 x institutional upper limit of normal (ULN) OR estimated creatinine clearance (CrCl) by the Cockcroft-Gault formula\n\n    ≥51mL\u002Fmin if creatinine \\> 1.5 x institutional ULN or institutional standard method\n  * INR OR PT and PTT ≤1.5 × institutional ULN unless participant is receiving anticoagulant therapy and PT\u002FINR or PTT are within therapeutic range of that anticoagulation\n* Participants with known brain metastases are eligible if they have completed primary CNS-directed therapy (such as surgical resection or radiotherapy) and if they have remained clinically stable, asymptomatic, radiologically stable without evidence of progression for at least 4 weeks by repeat imaging and have been off of steroids for at least 4 weeks prior to starting study treatment.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the Belzutifan, as determined after discussion with the Sponsor-Investigator, are eligible for this trial.\n* Archival tumor tissue must be available as 17 (15 unstained + 2 H\\&E) freshly serially cut slides from formalin-fixed, paraffin-embedded (FFPE) tissue blocks. The most recent available tissue is preferred to archived tissue. If fewer than 17 slides are available, the participant may still be eligible pending discussion with the Sponsor-Investigator.\n* The effects of Belzutifan on the developing human fetus are unknown. For this reason, women of child-bearing potential\\* must have a negative serum or urine pregnancy test at the Screening and Cycle 1 Day 1 visits. A negative serum or urine pregnancy test must be obtained within 24 hours before the first dose of study intervention in order to start receiving the study drug. Women of child-bearing potential and men must agree to use adequate contraception (see Appendix D) prior to study entry, for the duration of study participation, and for at least 30 days after last receipt of study therapy. Additionally, should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n\n  --Female participants who do not meet the definition of women of child-bearing potential must meet either criteria:\n  * Post-menopausal, defined as amenorrheic for at least 12 consecutive months within the appropriate age group and without an alternative medical cause OR\n  * Surgically sterilized (i.e. bilateral oophorectomy, bilateral tubal ligation or salpingectomy, or total hysterectomy)\n* Ability to swallow orally administered medications.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior use of Belzutifan or another HIF-2a inhibitor.\n* Participant has any of the following:\n\n  * Pulse oximeter reading \\\u003C92% at rest, or\n  * Requires intermittent supplemental oxygen, or\n  * Requires chronic supplemental oxygen\n* Anti-cancer treatment (chemotherapy, radiotherapy, or other investigational therapy) within 4 weeks prior to entering the study (6 weeks prior to study entry for nitrosoureas or mitomycin C).\n* Prior small molecule kinase inhibitor (including investigational kinase inhibitor) ≤ 2 weeks prior to entering the study.\n* Prior radiation therapy within 2 weeks of start of study drugs. Participants must have recovered from all radiation-related toxicities and must not require steroids. Participants must not have had radiation pneumonitis. Palliative radiation (≤2 weeks of radiotherapy) to non-CNS (central nervous system) disease is permitted, provided there is at least a 1-week washout prior to start of study drugs.\n* Use of herbal supplements, including but not limited to: cannabis, St. John's wort, gingko biloba, ginseng, saw palmetto, and ephedra. Herbal supplements must be stopped at least 1 week prior to beginning study treatment.\n* Participants who are known to require concomitant therapy with moderate or strong CYP3A4 inducers. Due to potential drug interactions, concomitant use of these medications is not permitted for the duration of treatment on trial. Participants are eligible for study entry if an appropriate substitution is made prior the first dose of study medication.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.\n* Participants who have AEs due to previous anticancer therapies must have recovered to\n\n  * Grade 1 or baseline with the exception of alopecia. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have\n  * Grade 2 neuropathy are eligible.\n* Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines are allowed.\n\nNote: Any licensed COVID-19 vaccine (including for Emergency Use) in a particular country is allowed in the study as long as they are mRNA vaccines, replication-incompetent adenoviral vaccines, or inactivated vaccines. These vaccines will be treated just as any other concomitant therapy.\n\n* Major surgical procedures within 4 weeks of beginning study treatment are not allowed. Minor surgical procedures (with the exception of port placement) within 1 week of beginning study treatment are not allowed.\n* Any gastrointestinal disorder that would interfere with the passage or absorption of oral medications. Participants must be able to swallow oral medications. Participants with an enteric tube (e.g., gastrostomy or jejunostomy tube), receiving total parenteral nutrition (TPN), or dependent on IV fluid support are ineligible.\n* Participants with significant cardiovascular impairment, including uncontrolled hypertension, congestive heart failure of New York Heart Association Grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia within the past 6 months.\n* Has moderate to severe hepatic impairment (Child-Pugh B or C).\n* Has received colony-stimulating factors (e.g., G-CSF, GM-CSF, or recombinant EPO)\n\n  ≤28 days prior to the first dose of study intervention.\n* Has a diagnosis of immunodeficiency.\n* Is known to be positive for Human Immunodeficiency Virus (HIV). Subjects with HIV, including those on antiretroviral therapy, are excluded due to risk of immunodeficiency and risk of overlapping toxicity.\n* Is known to be positive for Hepatitis B virus (HBV) or Hepatitis C virus (HCV). Participants are eligible if they have a history of HCV infection that has been treated and cured, with an undetectable viral load.\n* Participants with uncontrolled intercurrent illness, including but not limited to active infection and serious non-healing wounds or ulcers.\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Participants with a history of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biological composition to belzutifan.\n* Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with belzutifan, breastfeeding participants are excluded from this study.\n* History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.",{"count":400,"type":22},32,[171],"The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometriosis-related cancer.\n\nThe name of the study drug involved in this study is:\n\n\\- Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor)",[40,404,30,276,29,52,357,51],"Ovarian Carcinoma",[40,404,406,407,408,409,410,411,276,30,29,52,412,357,51],"Persistent Clear Cell Ovarian Carcinoma","Recurrent Clear Cell Ovarian Carcinoma","Clear Cell Uterine Carcinoma","Clear Cell Endometrial Carcinoma","Clear Cell Cervical Carcinoma","Clear Cell Vulvar Carcinoma","Gynecologic Malignancy","2025-11-03",{"date":415,"type":57},"2025-11-05",{"date":417,"type":57},"2024-12-20",{"date":419,"type":22},"2029-06-30",{"name":421,"class":134},"Dana-Farber Cancer Institute",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":268,"minAge":18,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":161},"100540263","radiochemotherapy-and-interventional-radiotherapy-in-vaginal-cancer-100540263","NCT06314568","Radiochemotherapy and Interventional Radiotherapy in Vaginal Cancer","Radiochemotherapy Treatment Followed by Interventional Radiotherapy in Patients Affected by Vagina Carcinoma Multi-centric Prospective Observational Study Trimodal Definitive Invasive Vaginal Carcinoma Treatment","TRIDENT","Inclusion Criteria:\n\n* Age more than18 years old\n* Performance status 0,1\n* Hystological diagnosis of squamous vaginal cancer\n* HPV, p16, p53 status\n* Stage I, II, III and IV (AJCC 2018th version)\n* Stadiation with magnetic resonance and positron emission tomography\n* Informed consensus\n\nExclusion Criteria:\n\n* Age inferior 18 years old\n* Performance status more than 2\n* Previous cancer in the last ten years\n* Previous radiation treatment in the region of interest\n* Presence of pathologies that contraindicate radiotherapy treatment (genetic syndromes of hyper-radiosensitivity, ulcerative colitis, diverticulitis in the acute phase, severe diverticulosis, chronic pelvic inflammation)\n* Presence of internal pathologies that contraindicate chemotherapy or radio-chemotherapy treatment (severe liver disease, heart disease, renal failure, etc.)\n* Presence of distant metastases in sites other than the pelvic lymph nodes\n* Any significant medical condition that in the opinion of the investigator may interfere with the patient's optimal participation in the study",{"count":431,"type":22},278,"Prospective observational multicenter study, aimed at evaluating the effectiveness on local control and cancer-specific survival of radiochemotherapy followed by interventional radiotherapy in patients affected by vaginal cancer",[51],"2025-08-12",{"date":436,"type":57},"2025-08-15",{"date":438,"type":57},"2024-03-15",{"date":440,"type":22},"2028-12-31",{"name":442,"class":134},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":17,"minAge":449,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":452,"conditions":453,"keywords":478,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":161},"100531692","nyscf-scientific-discovery-biobank-100531692","NCT06203106","NYSCF Scientific Discovery Biobank","Inclusion Criteria:\n\n* Age 30 days or older.\n* Diagnosis and\u002For medical history of a condition, disease, genetic background, or trait of interest or healthy control.\n* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.\n* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD\u002FADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and\u002For Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.\n* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental\u002Fguardian consent.\n* Minors undergoing blood, and\u002For saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n\nExclusion Criteria:\n\n* Wards of the state.\n* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.\n* For prospective blood samples: history of coagulation disorder.\n* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and\u002For a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.","30 Days",{"count":451,"type":22},10000,"The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.\n\nThrough this research, researchers hope to identify future treatments or even cures for the major diseases of our time.",[454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,40,29,276,51,52,476,477],"ALS","Amyotrophic Lateral Sclerosis","Alzheimer Disease","Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Batten Disease","Corticobasal Degeneration","Dementia","Frontotemporal Dementia","Huntington Disease","Lewy Body Disease","Multiple Sclerosis","Multiple System Atrophy","Parkinson Disease","Parkinson's Disease and Parkinsonism","Progressive Supranuclear Palsy","INAD","Diabetes","Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Macular Degeneration","PTSD","Post Traumatic Stress Disorder",[454,455,456,459,460,461,462,463,464,465,466,467,479,469,470,471,480,481,475,482,40,29,276,51,52,476,477],"Parkinsonism","Diabetes Type 1","Diabetes Type 2","Women's Reproductive Cancer","2025-02-27",{"date":485,"type":57},"2025-03-03",{"date":487,"type":57},"2022-11-10",{"date":489,"type":22},"2045-11-10",{"name":491,"class":134},"New York Stem Cell Foundation Research Institute",{"id":493,"slug":494,"hasResults":11,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":73,"sex":268,"minAge":18,"maxAge":78,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":501,"conditions":502,"keywords":506,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":161},"100057410","specimen-and-data-study-for-ovarian-cancer-early-detection-and-prevention-100057410","NCT00005095","Specimen and Data Study for Ovarian Cancer Early Detection and Prevention","Northwestern Ovarian Cancer Early Detection & Prevention Program: A Specimen and Data Study","DISEASE CHARACTERISTICS:\n\n* Meets one of the following criteria:\n\n  * Considered to be at increased risk for developing ovarian cancer, as defined by one of the following:\n\n    * Has at least one first-degree relative (mother, sister, or daughter) with ovarian, primary peritoneal, or fallopian tube cancer\n    * Has at least two first or second degree relatives diagnosed before age 50 with either ovarian, primary peritoneal, fallopian tube, and\u002For pancreatic cancer who have tested positive for hereditary cancer syndrome that includes an increased risk of gynecologic cancer (e.g., BRCA1\u002F2 or Lynch Syndrome)or have increased risk as deemed by a certified genetic counselor\n    * A personal or family history of a hereditary cancer syndrome that includes an increased risk of gynecologic cancer\n    * Increased risk as deemed by a certified genetic counselor\n  * Undergoing surgery for a gynecologic condition, including any of the following:\n\n    * Diagnosis of a reproductive cancer\n    * Benign gynecological condition (e.g., uterine leiomyomata, endometriosis, pelvic inflammatory disease, or follicular or corpus luteum ovarian cysts)\n    * Highly suspicious adnexal mass\n    * Risk-reducing prophylactic oophorectomy\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Between the ages of 18 and 80",{"count":500,"type":22},6000,"RATIONALE: To improve strategies for detection and prevention of early-stage disease.\n\nPURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.",[29,30,503,504,40,45,505,51,52],"Fallopian Tube Cancer","Hereditary Breast\u002FOvarian Cancer (brca1, brca2)","Uterine Leiomyomata",[507,508,509,510,511,512,513,514,211,207,210,515],"ovarian epithelial cancer","hereditary breast\u002Fovarian cancer (BRCA1, BRCA2)","fallopian tube cancer","ovarian germ cell tumor","ovarian sarcoma","ovarian stromal cancer","endometrial cancer","uterine sarcoma","uterine leiomyomata","2025-02-26",{"date":518,"type":57},"2025-02-28",{"date":520,"type":57},"2000-03",{"date":522,"type":22},"2040-12",{"name":293,"class":134},{"id":525,"slug":526,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":268,"minAge":18,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":534,"conditions":535,"keywords":538,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":161},"100537939","the-gynecological-cancer-associated-thrombosis-gyncat-study-100537939","NCT06284343","The Gynecological Cancer Associated Thrombosis (GynCAT) Study","Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study","GynCAT","Inclusion Criteria:\n\n* Female sex;\n* Diagnosis of gynecologic neoplasm (ovarian, tubal, uterine, cervical, vaginal, vulvar neoplasm);\n* Planned new line of systemic antineoplastic treatment;\n* Age of 18 years or older;\n* Accordance of Informed Consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women;\n* Indication to receive therapeutic dose anticoagulant therapy (e.g., atrial fibrillation, mechanical heart valve);\n* Diagnosis of symptomatic VTE at the time of screening for enrollment.",{"count":533,"type":22},1800,"GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM) for Venous Thromboembolism (VTE) in this specific population.",[536,537,357,40,277,30,51],"Cancer-associated Thrombosis","Venous Thromboembolism",[539,540,541,40,51,30,357],"Thrombosis","Venous thromboembolism","Cancer","2024-09-17",{"date":544,"type":57},"2024-09-19",{"date":546,"type":57},"2024-04-15",{"date":548,"type":22},"2026-09-30",{"name":442,"class":134},{"id":551,"slug":552,"hasResults":11,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":146,"phases":559,"briefSummary":560,"conditions":561,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":161},"100557946","phase-1-scg142-tcr-t-cells-for-human-papillomavirus-associated-carcinomas-100557946","NCT06544720","SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas","A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas","Key Inclusion Criteria:\n\n1. Greater than or equal to 18 years of age\n2. HPV associated carcinomas\n3. Patients must have at least one measurable lesion defined by RECIST 1.1\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\nKey Exclusion Criteria:\n\n1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.\n2. Patients with active autoimmune diseases.\n3. Patient has a known active Hepatitis B or Hepatitis C.\n4. Other severe medical conditions that may limit subject\\'s participation in this trial.",{"count":558,"type":22},18,[235],"A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.",[562,29,563,27,175,51,95,177],"Human Papillomavirus Associated Carcinomas","Head and Neck Cancers","2024-08-06",{"date":566,"type":57},"2024-08-09",{"date":568,"type":57},"2023-08-02",{"date":570,"type":22},"2026-12-31",{"name":572,"class":134},"The Affiliated Hospital of Qingdao University",{"id":574,"slug":575,"hasResults":11,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":73,"sex":268,"minAge":580,"maxAge":581,"enrollmentInfo":582,"targetDuration":4,"studyType":146,"phases":584,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":161},"100394922","phase-3-evaluate-the-efficacy-immunogenicity-and-safety-of-9-valent-hpv-recombinant-vaccine-in-chinese-healthy-females-100394922","NCT04422366","Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years","Inclusion Criteria:\n\n(If the \"\\*\" option is not met during screening, the visit can be rescheduled)\n\n* Chinese women aged 20-45 who can provide legal identification and have a sexual life history;\n* The subject fully understands the study procedures, understands the risks and benefits associated with participating in the study, and voluntarily signs the informed consent;\n* Subjects are able to read, understand and fill in application forms such as diary CARDS and contact CARDS, and participate in follow-up according to the study requirements;\n* Subjects have not been screened for cervical cancer, or have been screened for cervical cancer but the results are normal;\n* \\*0 days before the gynecological visit, no sex within 48 hours, no flushing or vaginal cleaning within 72 hours, no use of vaginal drugs or preparations;Subject agrees to refrain from sexual intercourse (including anal, vaginal, or genital\u002Fgenital contact of the same or opposite sex) for 48 hours prior to any visit that includes gynecological sample collection, and to refrain from vaginal flushing, vaginal cleansing, or use of vaginal medications or preparations for 72 hours;\n* When the subjects were enrolled, the urine pregnancy test was negative (sensitivity was 25mIU\u002Fml cox-hcg), they were not in the lactation period and had no family planning within 7 months after enrollment (1 month before whole-course inoculation).2 weeks before included in the study, effective contraceptive measures has been adopted and agreed to in the first seven months after the study (vaccinations after 1 months ago) continue to adopt effective contraceptive measures (effective contraceptive measures include: the pill, injection or embedded contraception, slow-release local birth control pills, hormone patch, the intrauterine device (IUD), sterilization, abstinence, condom (men), diaphragm, cervical cap, etc.), rhythm, withdrawal and emergency contraception is unacceptable contraception;\n* \\*body temperature \\\u003C37.3℃ (underarm body temperature)\n\nExclusion Criteria:\n\nFirst dose exclusion criteria(If the \"\\*\" option is met during screening, the visit can be rescheduled)\n\n* Have been vaccinated with commercially available HPV vaccine in the past or planned to be vaccinated with commercially available HPV vaccine during the study period;Or have participated in a clinical trial of the HPV vaccine and have received a vaccine\u002Fplacebo vaccination;\n* Previous positive history of HPV;\n* Has a history of abnormal cervical cytology, including squamous intraepithelial lesions (SIL) or not clear meaning of the atypical squamous cells (ASC - US), except the atypical squamous cells - not highly squamous intraepithelial lesion (ASC - H), atypical glandular epithelial cells, or those with cervical intraepithelial neoplasia (CIN) and carcinoma in situ or abnormal cervical biopsy results such as the history;\n* Past history of anal and genital diseases (such as vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, vulvar cancer, vaginal cancer and anal cancer, etc.);\n* Received total hysterectomy or pelvic radiotherapy;\n* Cervical insufficiency or abnormal cervical structure (judged by the results of routine gynecological examination);\n* Previous sexual history (including syphilis, gonorrhea, chancre, venereal lymphatic granuloma, granuloma inguinal) or have obvious condyloma;\n* A history of seizures, convulsions or convulsions, or a family history of mental illness;\n* Have participated in other gynecology-related clinical trials within 6 months, and have used or plan to use other investigational or unregistered products (drugs or vaccines) other than the vaccine in this study within 3 months;\n* A history of severe allergies requiring medical intervention, such as anaphylactic shock, anaphylactic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), etc.A history of severe adverse reactions to previous vaccinations or a history of severe allergies to any of the components of the vaccine under study (histidine, polysorbate, aluminum phosphate, sodium borate, amorphous aluminum phosphate sulfate adjuvant and water for injection) (such as swelling of the mouth and throat, dyspnea, hypotension or shock, severe urticaria, etc.);\n* Subject receives any immunoglobulin or blood product within 3 months prior to the first dose of vaccination, or plans to receive such product within the next 7 months (1 month prior to the full course of vaccination);\n* Subjects present\u002Fpresent with immune impairment or have been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases;\n* Immunosuppressant therapy within 1 month before the first dose of vaccination, such as long-term use of systemic glucocorticoid therapy (≥2mg\u002Fkg\u002F day, for more than 2 weeks, such as prednisone or similar drugs;Topical administration (such as ointment, eye drops, inhalant or nasal spray) not exceeding the recommended dosage in the directions or showing any signs of systemic exposure) or planning to receive such treatment within the next 7 months (1 month before the full course of inoculation);\n* Absence of spleen or functional absence of spleen, and absence of spleen or splenectomy in any case;\n* Patients with severe liver, kidney and cardiovascular diseases, diabetes or malignant tumor with complications;\n* Patients with thrombocytopenia or any coagulation disorders that may be contraindications to intramuscular injection;\n* \\* subjects received inactivated or recombinant vaccines within 14 days prior to study enrollment, or attenuated live vaccines within 28 days prior to study enrollment;\n* \\* an acute illness or an acute episode of a chronic illness within 3 days prior to vaccination or the use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.);\n* \\* the first dose of vaccine was in pregnancy at the time of vaccination, or the end of pregnancy had not exceeded 6 weeks;\n* \\* after questioning, subjects had fever symptoms (subaxillary body temperature ≥37.3℃) before the first day of vaccination (within 24 hours before vaccination);\n* \\* the subject is in the menstrual period;\n* \\* severe acute vaginitis and suppurative cervicitis found by naked eye during gynecological examination (purulent secretion visible by naked eye);\n* Blood pressure on physical examination before the first dose of vaccination was higher than normal or increased (systolic blood pressure ≥140mmHg and\u002For diastolic blood pressure ≥90mmHg);\n* Gynecological examination before the first dose of vaccination suspected genital warts, or on the basis of clinical symptoms and signs suspected vulva, vagina or cervical precancerous lesions and the possibility of cancer;\n* Subjects may be unable to comply with the study procedure, comply with the agreement, or plan to permanently relocate from the region prior to completion of the study, or may be permanently absent from the region during the scheduled visit;\n* In the opinion of the investigators, the subjects had any other factors that made them unsuitable to participate in the clinical trial, so that continued participation in the study could not guarantee the maximum benefit of the subjects.\n\nSecond and third doses of vaccine were excluded criteria\n\n* new discoveries or new occurrences that meet the first dose exclusion criteria (except for articles 2, 3, 4, 21);\n* other serious adverse events: the investigator decides whether to terminate the experimental vaccination according to its treatment needs;\n* the investigator assays for any other reasons that may be considered necessary to terminate the trial vaccination.\n\nSecond and third doses of vaccine were delayed criteria\n\nVaccination may be postponed if:\n\n* fever (underarm body temperature ≥37.3℃);\n* before inoculation (on the day of inoculation), the urine pregnancy test was positive (sensitivity was 25mIU\u002Fml n-hcg);\n* acute illness or acute attack of a chronic disease or use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) within 3 days before vaccination;\n* insufficient interval between other vaccines (inactivated or recombinant vaccines received within 14 days prior to vaccination, or any live attenuated vaccine received within 28 days);\n* any immunoglobulin or blood products received during vaccination should be administered at least 3 months after the vaccination;\n* other circumstances that can be postponed as judged by the researcher.","20 Years","45 Years",{"count":583,"type":22},8000,[585],"PHASE3","This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .",[29,52,51,588,589,590,591,592,593,594,595,596,597,598],"CIN1","CIN2","CIN3","VaIN1","VaIN2","VaIN3","Genital Wart","VIN 1","VIN 2","VIN 3","AIS","2024-06-06",{"date":601,"type":57},"2024-06-07",{"date":603,"type":57},"2020-04-28",{"date":605,"type":22},"2029-09-15",{"name":607,"class":64},"Shanghai Bovax Biotechnology Co., Ltd.",{"id":609,"slug":610,"hasResults":11,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":4,"eligibilityCriteria":614,"healthyVolunteers":73,"sex":268,"minAge":615,"maxAge":581,"enrollmentInfo":616,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":618,"conditions":619,"keywords":622,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":260},"100467790","immune-persistence-after-the-whole-vaccination-shcedule-with-recombination-quadrivalent-hpv-vaccine-100467790","NCT05371353","Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine","Evaluating the Immune Persistence of Recombination Quadrivalent HPV Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomized Clinical Trial","Inclusion Criteria:\n\n* Subjects who participated in the phase III clinical trial of non inferior efficacy of HPV tetravalent vaccine of Yangchun Center for Disease Control and Prevention (protocol No.: 4-HPV-3001), completed three doses of HPV quadrivalent vaccine and provided blood sample at months 7; Or subjects who have participated in the bridging study of HPV quadrivalent vaccine of Mianyang Center for Disease Control and Prevention (scheme No.: 4-HPV-3002), completed the whole vaccine schedule at month 0，2，6, and provided blood sample at months 7;\n* The subjects aged 9 to 17 years old at Mianyang site and their legal guardian should provide legal indentification; the subjects aged over 18 years old should provide legal indentification;\n* The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form;\n* Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements.\n\nExclusion Criteria:\n\n* Enrolling or plan to enroll in other clinical trials (drugs or vaccines) (except that the observational clinical study and the subjects at Mianyang site are still in the post exemption safety follow-up stage of the 4-HPV-3002 trial);\n* Suffering from thrombocytopenia or any coagulation dysfunction that can be a contraindication to blood collection (such as coagulation factor deficiency, coagulation diseases, platelet abnormalities, etc.);\n* According to the investigator's judgment, the subject has any condition may interfere with process of evaluation of immune persistence.","9 Years",{"count":617,"type":22},600,"To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.",[620,621,51,594,588,589,590],"HPV Infections","Cervical Cancer Stage IIa",[623,624,29],"Human papillomavirus","vaccine",{"date":626,"type":57},"2024-04-17",{"date":628,"type":57},"2022-05-14",{"date":630,"type":22},"2027-05",{"name":607,"class":64},{"id":633,"slug":634,"hasResults":11,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":73,"sex":268,"minAge":615,"maxAge":639,"enrollmentInfo":640,"targetDuration":4,"studyType":146,"phases":642,"briefSummary":643,"conditions":644,"keywords":645,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":646,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":161},"100441393","phase-3-immunogenicity-and-safety-of-quadrivalent-hpv-vaccine-in-healthy-chinese-female-subjects-aged-9-to-19-years-100441393","NCT05027776","Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial","Inclusion Criteria:\n\n1. Healthy Chinese females aged 9 to 26 years; Provide legal identification;\n2. The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form;\n3. Had a negative urine pregnancy test on the day of enrollment, among the subjects of childbearing age; Not in the duration of breast-feeding and no birth plan within 7 months; According to the investigator's judgment that there is no possibility of pregnancy at that time: subjects have taken effective contraception, or asexual life after the last menstrual period, or use IUD, or had undergone ligation; subjects agree to continue take effective contraception such as taking OCS and condom use;\n4. No fever symptoms on the day of enrollment (aged\\> 14 years old, axillary temperature\\\u003C37.3°C; aged ≤ 14 years old, axillary temperature\\\u003C37.5°C );\n5. Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements;\n\nExclusion Criteria:\n\n1. Received marketed HPV vaccine or plan to receive marketed HPV vaccine during this study period or have enrolled in HPV vaccine clinical trials;\n2. Enrolling or plan to enroll in other clinical trials (drug or vaccine);\n3. History of positive test to HPV, history of cervical cancer (e.g. abnormal screening test results, abnormal cervical biopsy results, including CIN, LSIL, and cervical cancer) or history of pelvic radiotherapyherpes;\n4. History of diseases related to HPV infection (e.g. genital warts, VIN, VaIN, and related cancers) or history of STDs, including syphilis, gonorrhea, genital herpes, Mycoplasma genitalium, Lymphgranuloma Venereum, granuloma inguinale, etc.;\n5. Known allergy to any vaccine components or history of severe allergic diseases requiring treatment, including shock, laryngeal edema, urticarial, Henoch-Schonlein purpura, Arthus reaction, etc.;\n6. Had primary or acquired immunodeficiency such as HIV, SLE, JRA, etc;\n7. History of epilepsy and convulsions (except fever convulsions in children under 5 years of age);\n8. Subjects with existing infectious diseases such as TB, viral hepatitis, and\u002For HIV infection; or existing liver or kidney conditions, CVDs, and malignancy;\n9. Untreated\u002Funcontrolled hypertension before vaccination (aged 9 to 17 years: systolic BP≥120mmHg and\u002For diastolic BP≥80mmHg; aged more than 18 years: Systolic BP≥140mmHg and\u002For diastolic BP ≥90mmHg);\n10. With prohibitive contraindications such as Thrombocytopenia or coagulopathy;\n11. Asplenic, functionally asplenic, or splenectomy caused by any condition;\n12. Received immunosuppressive treatment within one month before study such as long-term glucocorticoid use(≥2mg per kg per day, lasted more than two wks), or plan to receive such treatment from month 0 to month 7；\n13. Receipt of immune globulin or blood-related products within 3 months; or plan to receive such products during this study period（month 0 to month 7）;\n14. Within 3 days prior to vaccination, have an acute disease or are in the acute attack of a chronic disease or have used antipyretic, analgesic and anti-allergic drugs (such as: acetaminophen, ibuprofen, aspirin, loratadine, ceti Rizine, etc.);\n15. Receipt of inactivated, RNA, and recombinant vaccines within 14 days, live vaccines within 28 days;\n16. Subjects with existing mental illness, History of mental illness, or Family History;\n17. According to the investigator's judgment, the subject has any condition may interfere with process of evaluation or participating in this study cannot guarantee the object's maximum benefit.","26 Years",{"count":641,"type":22},1348,[585],"This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years",[620,621,51,594,588,589,590],[623,624,29],{"date":626,"type":57},{"date":648,"type":57},"2021-09-15",{"date":650,"type":22},"2026-09-29",{"name":607,"class":64},{"id":653,"slug":654,"hasResults":11,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":658,"eligibilityCriteria":659,"healthyVolunteers":11,"sex":268,"minAge":18,"maxAge":78,"enrollmentInfo":660,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":662,"conditions":663,"keywords":667,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":161},"100457918","retrospective-study-of-brachytherapy-100457918","NCT05242861","Retrospective Study of Brachytherapy","A Retrospective Study of Brachytherapy in Gynecological Cancers","RetroBT","Inclusion Criteria:\n\n* 18 - 80 female\n* Underwent brachytherapy\n* With gynecological cancer\n\nExclusion Criteria:\n\n* Refusal to enter this trial",{"count":661,"type":22},300,"Brachytherapy for gynecological cancers will be studied retrospectively.",[307,664,665,52,51,666,306],"Uterine Cervical Neoplasms","Uterine Neoplasms","Ovarian Neoplasms",[307,29,30,51,52,668,669],"Image Guided","3D Print","2022-02-06",{"date":672,"type":57},"2022-02-16",{"date":674,"type":22},"2022-02-20",{"date":676,"type":22},"2027-12-31",{"name":678,"class":134},"Zhejiang Cancer Hospital"]